Abstract
Alveolar soft-part sarcoma (ASPS) is a rare tumor. Cure is based solely on radical surgery. The general prognosis is poor. The tongue is an unusual site in adults, but not in children. Tumor removal can cause a severe impact on quality of life, even if reconstruction is possible. ASPS is a highly vascularized tumor and antiangiogenic therapy may have a role. We describe the use of the antiangiogenic combination bevacizumab and celecoxib in the preoperative management of a patient with an ASPS of the tongue.
Copyright © 2011 Wiley-Liss, Inc.
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Bevacizumab
-
Celecoxib
-
Child, Preschool
-
Female
-
Humans
-
Neovascularization, Pathologic / diagnosis
-
Neovascularization, Pathologic / drug therapy*
-
Pyrazoles / therapeutic use
-
Quality of Life
-
Sarcoma, Alveolar Soft Part / diagnosis
-
Sarcoma, Alveolar Soft Part / drug therapy*
-
Sarcoma, Alveolar Soft Part / surgery
-
Sulfonamides / therapeutic use
-
Tongue Neoplasms / diagnosis
-
Tongue Neoplasms / drug therapy*
-
Tongue Neoplasms / surgery
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Pyrazoles
-
Sulfonamides
-
Bevacizumab
-
Celecoxib